Revumenib Is Safe and Efficacious, but MEN1 Mutations Mediate Resistance

Article navigation

Research Watch| May 04 2023

Online ISSN: 2159-8290

Print ISSN: 2159-8274

2023

American Association for Cancer Research

Cancer Discov (2023) 13 (5): 1038.

Abstract

Revumenib is well tolerated with clinical efficacy, and mutations in MEN1 mediate acquired resistance.

2023

American Association for Cancer Research

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.